These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
230 related articles for article (PubMed ID: 22210558)
1. Potential role for therapies targeting DKK1, LRP5, and serotonin in the treatment of osteoporosis. Zhang W; Drake MT Curr Osteoporos Rep; 2012 Mar; 10(1):93-100. PubMed ID: 22210558 [TBL] [Abstract][Full Text] [Related]
2. Where Wnts went: the exploding field of Lrp5 and Lrp6 signaling in bone. Williams BO; Insogna KL J Bone Miner Res; 2009 Feb; 24(2):171-8. PubMed ID: 19072724 [TBL] [Abstract][Full Text] [Related]
3. LRP5 mutations in osteoporosis-pseudoglioma syndrome and high-bone-mass disorders. Levasseur R; Lacombe D; de Vernejoul MC Joint Bone Spine; 2005 May; 72(3):207-14. PubMed ID: 15850991 [TBL] [Abstract][Full Text] [Related]
4. Targeting WNT signaling in the treatment of osteoporosis. Baron R; Gori F Curr Opin Pharmacol; 2018 Jun; 40():134-141. PubMed ID: 29753194 [TBL] [Abstract][Full Text] [Related]
5. Role of Wnt signaling and sclerostin in bone and as therapeutic targets in skeletal disorders. Marini F; Giusti F; Palmini G; Brandi ML Osteoporos Int; 2023 Feb; 34(2):213-238. PubMed ID: 35982318 [TBL] [Abstract][Full Text] [Related]
6. Sclerostin neutralization unleashes the osteoanabolic effects of Dkk1 inhibition. Witcher PC; Miner SE; Horan DJ; Bullock WA; Lim KE; Kang KS; Adaniya AL; Ross RD; Loots GG; Robling AG JCI Insight; 2018 Jun; 3(11):. PubMed ID: 29875318 [TBL] [Abstract][Full Text] [Related]
7. Mutations in LRP5 cause primary osteoporosis without features of OI by reducing Wnt signaling activity. Korvala J; Jüppner H; Mäkitie O; Sochett E; Schnabel D; Mora S; Bartels CF; Warman ML; Deraska D; Cole WG; Hartikka H; Ala-Kokko L; Männikkö M BMC Med Genet; 2012 Apr; 13():26. PubMed ID: 22487062 [TBL] [Abstract][Full Text] [Related]
8. Fructus Ligustri Lucidi preserves bone quality through induction of canonical Wnt/β-catenin signaling pathway in ovariectomized rats. Liu H; Guo Y; Zhu R; Wang L; Chen B; Tian Y; Li R; Ma R; Jia Q; Zhang H; Xia B; Li Y; Wang X; Zhu X; Zhang R; Brӧmme D; Gao S; Zhang D; Pei X Phytother Res; 2021 Jan; 35(1):424-441. PubMed ID: 32755017 [TBL] [Abstract][Full Text] [Related]
9. The emerging role of serotonin (5-hydroxytryptamine) in the skeleton and its mediation of the skeletal effects of low-density lipoprotein receptor-related protein 5 (LRP5). Warden SJ; Robling AG; Haney EM; Turner CH; Bliziotes MM Bone; 2010 Jan; 46(1):4-12. PubMed ID: 19591966 [TBL] [Abstract][Full Text] [Related]
10. Dkk1-mediated inhibition of Wnt signaling in bone results in osteopenia. Li J; Sarosi I; Cattley RC; Pretorius J; Asuncion F; Grisanti M; Morony S; Adamu S; Geng Z; Qiu W; Kostenuik P; Lacey DL; Simonet WS; Bolon B; Qian X; Shalhoub V; Ominsky MS; Zhu Ke H; Li X; Richards WG Bone; 2006 Oct; 39(4):754-66. PubMed ID: 16730481 [TBL] [Abstract][Full Text] [Related]
11. The role of Dickkopf-1 in bone development, homeostasis, and disease. Pinzone JJ; Hall BM; Thudi NK; Vonau M; Qiang YW; Rosol TJ; Shaughnessy JD Blood; 2009 Jan; 113(3):517-25. PubMed ID: 18687985 [TBL] [Abstract][Full Text] [Related]
12. Wnt signalling in osteoporosis: mechanisms and novel therapeutic approaches. Canalis E Nat Rev Endocrinol; 2013 Oct; 9(10):575-83. PubMed ID: 23938284 [TBL] [Abstract][Full Text] [Related]
13. [Wnt signaling molecules related to osteoporosis]. Kubota T; Ozono K Clin Calcium; 2013 Jun; 23(6):855-60. PubMed ID: 23719498 [TBL] [Abstract][Full Text] [Related]
14. Opposing Roles of Wnt Inhibitors IGFBP-4 and Dkk1 in Cardiac Ischemia by Differential Targeting of LRP5/6 and β-catenin. Wo D; Peng J; Ren DN; Qiu L; Chen J; Zhu Y; Yan Y; Yan H; Wu J; Ma E; Zhong TP; Chen Y; Liu Z; Liu S; Ao L; Liu Z; Jiang C; Peng J; Zou Y; Qian Q; Zhu W Circulation; 2016 Dec; 134(24):1991-2007. PubMed ID: 27803037 [TBL] [Abstract][Full Text] [Related]
15. More severe phenotype of early-onset osteoporosis associated with recessive form of LRP5 and combination with DKK1 or WNT3A. Caetano da Silva C; Ricquebourg M; Orcel P; Fabre S; Funck-Brentano T; Cohen-Solal M; Collet C Mol Genet Genomic Med; 2021 Jun; 9(6):e1681. PubMed ID: 33939331 [TBL] [Abstract][Full Text] [Related]
16. Pathogenic mutations and polymorphisms in the lipoprotein receptor-related protein 5 reveal a new biological pathway for the control of bone mass. Ferrari SL; Deutsch S; Antonarakis SE Curr Opin Lipidol; 2005 Apr; 16(2):207-14. PubMed ID: 15767861 [TBL] [Abstract][Full Text] [Related]
17. Heterozygous deletion of LRP5 gene in mice alters profile of immune cells and modulates differentiation of osteoblasts. Li L; Wang Y; Zhang N; Zhang Y; Lin J; Qiu X; Gui Y; Wang F; Li D; Wang L Biosci Trends; 2018 Jul; 12(3):266-274. PubMed ID: 29899194 [TBL] [Abstract][Full Text] [Related]
18. Reversing LRP5-dependent osteoporosis and SOST deficiency-induced sclerosing bone disorders by altering WNT signaling activity. Chang MK; Kramer I; Keller H; Gooi JH; Collett C; Jenkins D; Ettenberg SA; Cong F; Halleux C; Kneissel M J Bone Miner Res; 2014 Jan; 29(1):29-42. PubMed ID: 23901037 [TBL] [Abstract][Full Text] [Related]
19. The Wnt co-receptor LRP5 is essential for skeletal mechanotransduction but not for the anabolic bone response to parathyroid hormone treatment. Sawakami K; Robling AG; Ai M; Pitner ND; Liu D; Warden SJ; Li J; Maye P; Rowe DW; Duncan RL; Warman ML; Turner CH J Biol Chem; 2006 Aug; 281(33):23698-711. PubMed ID: 16790443 [TBL] [Abstract][Full Text] [Related]
20. [Anti-Dickkopf1 (Dkk1) antibody as a bone anabolic agent for the treatment of osteoporosis]. Tai N; Inoue D Clin Calcium; 2014 Jan; 24(1):75-83. PubMed ID: 24369283 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]